Trial reportPloS one2025
Nurse-led secondary preventive follow-up after stroke/TIA and ACS for patients aged 80 years or older: A post-hoc analysis of the randomized controlled NAILED trial.
Trial report in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe evidence supporting secondary prevention with antihypertensives and lipid-lowering drugs after cerebrovascular disease or acute coronary syndrome (ACS) is not as strong for persons aged ≥80 years. The Nurse-based, Age-independent Intervention to Limit Evolution of Disease (NAILED) trial was a randomized controlled trial in which secondary preventive follow-up with titration of antihypertensives and lipid-lowering drugs was compared to usual care. In this substudy, we investigated the efficacy and safety of the NAILED intervention in persons aged ≥80 years. METHODS AND
findingsPatients admitted to Östersund Hospital with ACS, stroke, or transient ischemic attack between 2010 and 2014 were randomized to a nurse-led telephone-based follow-up (intervention group) or usual care (control group) and followed from discharge until 31 December 2017, with a maximum follow-up of 5 years. This post-hoc analysis included all patients aged ≥80 years (n = 394). The primary outcome was a composite of cardiovascular death, myocardial infarction, and stroke. The secondary endpoints were cardiovascular death, myocardial infarction, stroke, ischemic stroke, all-cause mortality, fracture, orthostatic hypotension, serious bleeding, and health-related quality of life. During a mean follow-up of 3.8 years, 31.7% (n = 64) of the patients in the intervention group and 37.5% (n = 72) in the control group reached the primary endpoint (HR 0.82, 95% CI 0.58-1.14, P = 0.23). The risk of cardiovascular death was significantly decreased (HR 0.64, 95% CI 0.41-0.998, P = 0.049) and the risk of fracture non-significantly increased (HR 1.47, 95% CI 0.95-2.27, P = 0.08) in the intervention group compared to the control group.
conclusionsThe intervention in the NAILED trial did not reduce the risk of major cardiovascular events in patients aged ≥80 years. The trends of lower risk of cardiovascular events and increased risk of fractures need to be validated in future research.
trial registrationISRCTN23868518, ISRCTN96595458. The NAILED risk factor trial is registered in the ISRCTN registry, (ISRCTN23868518) for the stroke/TIA and (ISRCTN96595458) for the ACS cohort. The strict ICMJE requirement of prospective registration of clinical trials came to our attention when the recruitment had already begun. The study was therefore retrospectively registered on 19 June 2012. We confirm that all related and ongoing trials are now registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.